Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size - Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

The phosphoinositide 3-kinase (PI3K) inhibitors market was valued at USD 1.29 Billion in 2025 and is expected to grow at a CAGR of 7.30%, reaching USD 2.61 Billion by 2035. Growth is driven by rising incidence of cancers and ongoing development of targeted PI3K therapies.

Latest News on the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market (2026)

April 2026: Novartis Acquires Synnovation PI3K Alpha Inhibitor for 2 Billion

According to MedCity News, Novartis announced on March 20, 2026 a USD 2 billion deal to acquire Synnovation Therapeutics' next-generation mutant-selective PI3K alpha inhibitor SNV4818. The asset is positioned to enable safer triple-combination therapy in HR-positive HER2-negative breast cancer, reinforcing competitive realignment and accelerating innovation pipeline strength across the global PI3K inhibitors market amid rising precision oncology demand.

March 2026: Novartis Bets 2 Billion on Mutant Selective PI3K Alpha Inhibitor

According to OncoDaily, Novartis is paying USD 2 billion upfront for Synnovation's PI3K alpha inhibitor program in March 2026, with up to USD 1 billion in milestones, to revive triple therapy in breast cancer. The deal positions Novartis ahead of Roche's Itovebi and reinforces accelerating M&A momentum, pipeline diversification, and competitive innovation reshaping the global phosphoinositide 3-kinase inhibitors market.

Market Size and Forecast

• Market Size 2025: USD 1.29 Billion
• Projected Market Size in 2035: USD 2.61 Billion
• CAGR from 2026-2035: 7.30 %

Targeted therapy for small molecules uses PI3K inhibitors that are relatively new in the area of oncology treatment. The development in the field of targeted therapy and their approvals are driving the growth of the industry globally. The governments across the nations have taken various measures to cut down the cost of these drugs to help patients. Such programmes help patients receive treatment at an affordable price. Thus, the emergence of such reimbursement schemes is one of the key market developments that will fuel the growth of the phosphoinositide 3-kinase inhibitors industry over the forecast period.

Market Segmentation

A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a therapeutic drug class that works by inhibiting one or more of the 3-kinase phosphoinositide enzymes. The global phosphoinositide 3-kinase (PI3K) inhibitors industry can be broadly categorised based on its applications and regions.

Market Breakup by Application

• CLL - Chronic lymphocytic leukaemia
• FL - Follicular lymphoma

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Market Analysis

The rising prevalence of cancer around the globe has resulted in the increased demand for chemotherapy and other treatment procedures. Chemotherapy drugs play a significant role in treating cancer. Their drawbacks, however, have produced a change from conventional chemotherapy to targeted therapies. As a result, extensive ongoing research is being performed on targeted therapies such as PI3K inhibitors with demonstrated effectiveness in oncology applications. Significant R&D has contributed to tailored treatments in the dominant therapeutic category. Thus, the recent launches and approvals of targeted therapy during the forecast period will contribute to the growth of phosphoinositide 3-kinase (PI3K) inhibitors industry globally. Although the complex manufacturing process of such drugs makes them expensive, which is becoming a significant challenge for manufacturers and may hamper the industry growth over the forecast period.

Competitive Landscape

The report presents a detailed analysis of the following key players in the global phosphoinositide 3-kinase (PI3K) inhibitors market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Bayer AG
• Gilead Sciences Inc.
• Novartis AG
• TG Therapeutics Inc.
• Verastem Inc.
• Others

The report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.